Mydecine Innovations Group (CNSX:MYCO) - Stock Price, News & Analysis

MYCO Stock Overview

A biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. More details

MYCO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 8.7% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (CA$333K)

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

+ 2 more risks

Mydecine Innovations Group Inc. Competitors

Hempsana Holdings

CNSX:HMPS

CA$591.3k

SugarBud Craft Growers

TSXV:SUGR.H

CA$718.6k

Lophos Holdings

CNSX:MESC

CA$858.6k

RAMM Pharma

CNSX:RAMM

CA$2.4m

Price History & Performance

Summary of all time highs, changes and price drops for Mydecine Innovations Group
Historical stock prices
Current Share Price	US$0.01
52 Week High	US$0.14
52 Week Low	US$0.005
Beta	2.77
11 Month Change	0%
3 Month Change	-33.33%
1 Year Change	-90.91%
33 Year Change	-99.89%
5 Year Change	-99.93%
Change since IPO	-99.99%

Recent updates

Shareholder Returns

	MYCO	CA Pharmaceuticals	CA Market
7D	0%	1.7%	0.3%
1Y	-90.9%	-20.7%	23.0%

Return vs Industry: MYCO underperformed the Canadian Pharmaceuticals industry which returned -20.8% over the past year.

Return vs Market: MYCO underperformed the Canadian Market which returned 23.7% over the past year.

Price Volatility

Is MYCO's price volatile compared to industry and market?
MYCO volatility
MYCO Average Weekly Movement	80.3%
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	3.0%

Stable Share Price: MYCO's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: MYCO's weekly volatility has increased from 59% to 80% over the past year.

About the Company

Founded	Employees	CEO	Website
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005.

Mydecine Innovations Group Inc. Fundamentals Summary

How do Mydecine Innovations Group's earnings and revenue compare to its market cap?
MYCO fundamental statistics
Market cap	CA$467.37k
Earnings (TTM)	-CA$12.46m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MYCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYCO income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$12.46m
Earnings	-CA$12.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.20
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-37.4%

How did MYCO perform over the long term?

See historical performance and comparison

MYCO Stock Overview

Rewards

Risk Analysis

Mydecine Innovations Group Inc. Competitors

CNSX:HMPS

CA$591.3k

TSXV:SUGR.H

CA$718.6k

CNSX:MESC

CA$858.6k

CNSX:RAMM

CA$2.4m

Price History & Performance

Recent News & Updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Forecast to breakeven in 2023

Full year 2021 earnings: Revenues miss analyst expectations

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Forecast to breakeven in 2023

Shareholder Returns

Price Volatility

About the Company

Mydecine Innovations Group Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue